Observational Study for Small Cell Lung Cancer
This is an observational study called SCULPTOR for people with small cell lung cancer (SCLC). Researchers are not testing a new treatment; instead, they are observing participants who are receiving standard care. The study aims to understand if different patterns in tumor tissue (called transcriptional subtypes) can be found and how these patterns relate to how well patients do over time. To join, you must have a confirmed diagnosis of small cell lung cancer from a biopsy. The study plans to enroll 200 participants and is currently unclear about its recruitment status.
- Study design
- This is an observational study, meaning no intervention is given. It plans to include 200 participants.
- What's involved
- You would have your tumor tissue profiled at diagnosis and potentially after your disease progresses. Your blood will also be tested for biomarkers (like ctDNA and CTC) during your standard of care treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will follow up with participants for up to 4 years to see how their tumor tissue patterns relate to their clinical outcomes.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Tempus Small Cell Lung Cancer Observational Study (Sculptor)
At a glance
Conditions
Where it's being run
11 sites across 9 statesStudy leadership
- Virginia Rhodes, MD · PRINCIPAL_INVESTIGATOR · Tempus AI, Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To determine if tumor tissue transcriptional subtypes can be detectedUp to 4 years
To determine prospectively if SCLC tumor tissue transcriptional subtypes can be detected by RNAseq
- To characterize relationship between tissue transcriptional subtype and clinical outcomesUp to 4 years
To characterize the relationship between tissue transcriptional subtype and clinical outcomes for first and second line based on collection of longitudinal information from medical records